Literature DB >> 19882576

Inflammatory mediators and posterior segment involvement in ocular Behcet disease.

Yasemin Ozdamar1, Nilufer Berker, Gul Bahar, Emel Soykan, Tolga Bicer, Seyhan Sonar Ozkan, Jale Karakaya.   

Abstract

PURPOSE: To assess the serum level of mediators and their relation with posterior ocular involvement in patients with Behcet disease (BD).
METHODS: This study was a prospective, institutional clinical trial including 43 patients with ocular BD. Patients were divided into two subgroups: those with active posterior segment involvement (Group A) and those with inactive ocular BD (Group B). Group A included patients with posterior uveitis (vitritis or chorioretinal involvement), while Group B included patients with no active intraocular inflammation within the last 3 months. Serum levels of interleukin (IL)-6, IL-8, tumor necrosis factor alpha (TNF-alpha), vascular endothelial growth factor (VEGF), and malondialdehyde (MDA) were measured by sandwich enzyme-linked immunosorbent assay and spectrophotometric assay and compared among the groups by independent sample t test and Mann-Whitney U-test.
RESULTS: Serum levels of the mediators in Group A (IL-6 [23.1 pg/mL], IL-8 [161.1 pg/mL], TNF-alpha [30.5 pg/mL], VEGF [455.9 pg/mL], MDA [10.7 microm]) were found to be significantly higher than those in Group B (IL-6 [12.2 pg/mL], IL-8 [48.4 pg/mL], TNF-alpha [18.6 pg/mL], VEGF [138.0 pg/mL], MDA [5.1 microm]).
CONCLUSIONS: This study demonstrated that increased serum levels of inflammatory mediators including IL-6, IL-8, TNF-alpha, VEGF, and MDA were possibly involved in the development of posterior uveitis in BD.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19882576     DOI: 10.1177/112067210901900616

Source DB:  PubMed          Journal:  Eur J Ophthalmol        ISSN: 1120-6721            Impact factor:   1.922


  9 in total

1.  Anterior mediastinal fat in Behçet's disease: qualitative and quantitative CT analysis.

Authors:  Sang Yub Lee; Jongmin Lee; Hui Joong Lee; Sun Ju Choi; Myong Hun Hahm; Sung Won Yoon
Journal:  Int J Cardiovasc Imaging       Date:  2013-10-10       Impact factor: 2.357

2.  Infliximab exerts a dose-dependent effect on retinal safety in the albino rabbit.

Authors:  Shiri Zayit-Soudry; Igor Vainer; Esther Zemel; Michael Mimouni; Melvin Rabena; Dante J Pieramici; Ido Perlman; Anat Loewenstein
Journal:  Doc Ophthalmol       Date:  2017-08-19       Impact factor: 2.379

Review 3.  Behçet syndrome: from pathogenesis to novel therapies.

Authors:  Gianluigi Mazzoccoli; Angela Matarangolo; Rosa Rubino; Michele Inglese; Angelo De Cata
Journal:  Clin Exp Med       Date:  2014-12-02       Impact factor: 3.984

4.  Tocilizumab in the treatment of severe and refractory parenchymal neuro-Behçet's syndrome: case series and literature review.

Authors:  Jinjing Liu; Dong Yan; Zhimian Wang; Yunjiao Yang; Shangzhu Zhang; Di Wu; Lingyi Peng; Zhichun Liu; Wenjie Zheng
Journal:  Ther Adv Musculoskelet Dis       Date:  2020-11-16       Impact factor: 5.346

5.  Serum levels of Th17-related cytokines in Behcet disease patients after cataract surgery.

Authors:  Shuhong Jiang; Xialin Liu; Lixia Luo; Bo Qu; Xiangkun Huang; Ying Lin; Shaobi Ye; Yizhi Liu
Journal:  Mol Vis       Date:  2011-05-31       Impact factor: 2.367

6.  The Effectiveness of Pre- and Postoperative Infliximab in Controlling Behçet's Disease Posterior Uveitis in Patients Undergoing Vitrectomy: A Preliminary Study.

Authors:  Hossam El Din Mohamed Khalil; Heba A El Gendy; Hala Ahmed Raafat; Hazem Effat Haroun; Tamer Atef Gheita; Hossam Mahmoud Bakir
Journal:  J Ophthalmol       Date:  2017-04-04       Impact factor: 1.909

7.  Characteristics of Macular Edema in Behcet Disease after Intravitreal Bevacizumab Injection.

Authors:  Fariba Ghassemi; Sohrab Afshari Mirak; Hormoz Chams; Siamak Sabour; Mehdi Nilli Ahmadabadi; Fereidoun Davatchi; Farhad Shahram
Journal:  J Ophthalmic Vis Res       Date:  2017 Jan-Mar

8.  Saliva and Serum Cytokine Profiles During Oral Ulceration in Behçet's Disease.

Authors:  Tanya Novak; Mojgan Hamedi; Lesley Ann Bergmeier; Farida Fortune; Eleni Hagi-Pavli
Journal:  Front Immunol       Date:  2021-12-22       Impact factor: 7.561

9.  Pharmacological Inactivation of Src Family Kinases Inhibits LPS-Induced TNF-α Production in PBMC of Patients with Behçet's Disease.

Authors:  Sevgi Irtegun; Gulsum Pektanc; Zeynep M Akkurt; Mehtap Bozkurt; Fatih M Turkcu; Sevgi Kalkanli-Tas
Journal:  Mediators Inflamm       Date:  2016-06-30       Impact factor: 4.711

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.